SCHEMBL6934627

SCHEMBL6934627

CC(C)c1cccc(-c2c(-c3ccncc3)nc(NC[C@@H](N)Cc3ccccc3)n(C)c2=O)c1

nearest known ligand 0.82

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK9 P45984 3/20 0.82
MAP4K4 O95819 2/20 0.82
CSNK1D P48730 2/20 0.82
CDC42BPA Q5VT25 2/20 0.82
MINK1 Q8N4C8 2/20 0.82
FRK P42685 1/20 0.82
CSNK1A1 P48729 1/20 0.82
MAP4K5 Q9Y4K4 1/20 0.82
PRKCI P41743 15/20 0.81
MAPK13 O15264 2/20 0.81
MAPK14 Q16539 2/20 0.81
PRKCD Q05655 2/20 0.81
EGFR P00533 1/20 0.81
ERBB2 P04626 1/20 0.81
LYN P07948 1/20 0.81
PRKACA P17612 1/20 0.81
MAPK8 P45983 1/20 0.81
MAPK12 P53778 1/20 0.81
MAPK10 P53779 1/20 0.81
MAP3K10 Q02779 1/20 0.81

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6934628 1.00 MAPK9 (0.82) MAPK9MAP4K4CSNK1DCDC42BPAMINK1
SCHEMBL6934623 1.00 MAPK9 (0.82) MAPK9MAP4K4CSNK1DCDC42BPAMINK1
SCHEMBL8466187 0.93 PRKCI (0.73) MAPK9MAP4K4CSNK1DCDC42BPAMINK1
SCHEMBL8324691 0.90 MAPK9 (1.00) MAPK9MAP4K4CSNK1DCDC42BPAMINK1
SCHEMBL27525660 0.90 MAPK9 (0.84) MAPK9MAP4K4CSNK1DCDC42BPAMINK1
SCHEMBL27505941 0.90 MAPK9 (0.84) MAPK9MAP4K4CSNK1DCDC42BPAMINK1
SCHEMBL6934543 0.90 MAPK9 (1.00) MAPK9MAP4K4CSNK1DCDC42BPAMINK1
SCHEMBL6934545 0.90 MAPK9 (1.00) MAPK9MAP4K4CSNK1DCDC42BPAMINK1
SCHEMBL6931387 0.90 MAPK9 (0.82) MAPK9MAP4K4CSNK1DCDC42BPAMINK1
SCHEMBL6931385 0.90 MAPK9 (0.82) MAPK9MAP4K4CSNK1DCDC42BPAMINK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030073704-A1 Substituted pyridone compounds and methods of use AMGEN INC. 2003-04-17 US claimed
US-6096753-A Substituted pyrimidinone and pyridone compounds and methods of use AMGEN INC. (US) 2000-08-01 US claimed
US-6649604-B2 Analgesics; antidiabetic agents; antiinflamamtory agents AMGEN INC. 2003-11-18 US disclosed
US-20030073704-A1 Substituted pyridone compounds and methods of use AMGEN INC. 2003-04-17 US disclosed
US-6420385-B1 INFLAMMATORY, PAIN AND DIABETES DISEASES, AMGEN INC. 2002-07-16 US disclosed
US-6096753-A Substituted pyrimidinone and pyridone compounds and methods of use AMGEN INC. (US) 2000-08-01 US disclosed
EP-0948496-A2 SUBSTITUTED PYRIMIDINONE AND PYRIDONE COMPOUNDS AND METHODS OF USE Amgen inc. (US) 1999-10-13 EP disclosed
WO-1998024780-A2 SUBSTITUTED PYRIMIDINONE AND PYRIDINONE COMPOUNDS AND THEIR USE AMGEN INC. (US) 1998-06-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030073704-A1 Substituted pyridone compounds and methods of use IL6, IL1B, IL1A MAPK9 1247/4885MAP4K4 761/4885CSNK1D 1761/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.